【阿可替尼在华获批用于未经治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者】3月18日,阿斯利康阿可替尼 获中国国家药品监督管理局正式批准,本品单药适用于成人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者。这是阿可替尼在中国获批的第3项适应症,标志着其将同时适用于初治和经治的CLL/SLL患者。

金融界
26 Mar
3月18日,阿斯利康阿可替尼 获中国国家药品监督管理局正式批准,本品单药适用于成人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者。这是阿可替尼在中国获批的第3项适应症,标志着其将同时适用于初治和经治的CLL/SLL患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10